A 28-year-old man with a history of recurrent meningococcal infections (Neisseria meningitidis) is referred for immunological evaluation. Serum complement levels (C3, C4) are normal, and total immunoglobulin levels are normal. However, serum IgG subclass analysis shows severe deficiency of IgG2 (<5 mg/dL; normal 200–400). Vaccination with meningococcal polysaccharide vaccine does not elicit a protective response. Which structural feature of IgG2 explains its critical role in anti-polysaccharide immunity?

Explanation

## Clinical Context IgG2 deficiency is a well-recognized primary immunodeficiency associated with recurrent infections caused by **encapsulated bacteria** (Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae). Polysaccharide antigens are T-cell-independent and require IgG2 for optimal antibody response. ## Why IgG2 Structure is Critical **Key Point:** IgG2 has a **shorter hinge region** with **fewer disulfide bonds** (2 disulfide bonds in the hinge, compared to 2 in IgG1 but with a shorter peptide backbone) and markedly **reduced flexibility** compared to IgG1. This structural rigidity **limits Fc receptor binding** (particularly FcγRI and FcγRIII) and reduces complement activation efficiency relative to IgG1 and IgG3. **High-Yield Structural Facts (Janeway's Immunobiology / Roitt):** | Feature | IgG1 | IgG2 | IgG3 | IgG4 | |---|---|---|---|---| | **Hinge length (residues)** | 15 | **12 (shorter)** | 62 (longest) | 12 | | **Hinge disulfide bonds** | 2 | **4** | 11 | 2 | | **Hinge flexibility** | High | **Low (rigid)** | Very high | High | | **FcγRI binding** | Strong | **Weak** | Strong | Weak | | **FcγRIIa binding** | Moderate | **Moderate (allotype-dependent)** | Moderate | Weak | | **Complement activation** | Strong | **Weak–moderate** | Very strong | Weak | | **Primary antigen type** | Protein Ag | **Polysaccharide Ag** | Protein Ag | Protein Ag | **Note on Option B:** While IgG2 does have **four** hinge disulfide bonds, this creates a **rigid, constrained** structure that actually **reduces** (not enhances) Fc receptor engagement and complement fixation compared to IgG1. Option B incorrectly states that this rigidity allows "optimal Fc receptor engagement and complement fixation"—this is factually wrong. The reduced flexibility of IgG2 is a structural limitation, not an advantage for Fc-mediated effector functions. ## Why IgG2 Dominates Anti-Polysaccharide Responses Despite Structural Limitations IgG2 is the predominant antibody subclass elicited by **T-cell-independent type 2 (TI-2) antigens** such as bacterial capsular polysaccharides. This is due to: 1. **B-cell receptor signaling pathways** preferentially driving IgG2 class switching in response to repetitive polysaccharide epitopes 2. **Avidity compensation** — the rigid, bivalent IgG2 molecule can cross-link densely repeated polysaccharide epitopes on bacterial capsules 3. **Opsonization via FcγRIIa (CD32a)** — IgG2 binds FcγRIIa (particularly the H131 allotype) on neutrophils and macrophages, enabling phagocytosis of opsonized encapsulated bacteria **Clinical Pearl:** IgG2 deficiency is particularly problematic because: - Polysaccharide vaccines (meningococcal, pneumococcal) elicit poor IgG2 responses in deficient patients - Encapsulated bacteria evade opsonization and phagocytosis without IgG2 - Patients fail to respond to polysaccharide vaccination (as in this case) - Conjugate vaccines (polysaccharide linked to protein carrier) partially bypass this deficiency by recruiting T-cell help ## Why Option A is Correct The **shorter, less flexible hinge region** of IgG2 (with its four disulfide bonds creating rigidity) **limits Fc receptor binding** compared to IgG1. This is the defining structural feature that distinguishes IgG2 from other subclasses and explains both its restricted effector functions and its unique role in anti-polysaccharide immunity — it is the antibody subclass preferentially produced against polysaccharide antigens, even though its Fc-mediated effector functions are comparatively limited. [cite: Janeway's Immunobiology 9e, Ch 5; Roitt's Essential Immunology 13e; Harrison's Principles of Internal Medicine 21e Ch 372]